Inscripta picks up Solana to commercialize gene-editing tools

Inscripta will acquire Solana Biosciences to ramp up the commercialization of its gene-editing technology. The Boulder, Colorado-based biotech aims to broaden access to CRISPR by offering new enzymes for free and to boost CRISPR research by outfitting scientists with a full suite of tools.
Solana was founded in 2017 by a group of former Illumina employees that includes Tom Rosso, who was vice president of operations at the sequencing giant. While at Illumina, this team created adaptable and scalable manufacturing operations, a skill set Inscripta wants to tap—it plans to expand its operations and to open a new site in San Diego.
Once the deal closes, Rosso will take over operations at Inscripta and head up its process development, technology transfer, manufacturing, and operations teams. Financial details were not disclosed.